RT info:eu-repo/semantics/article
T1 Type 1 and CD103+ Type 2 Conventional Dendritic Cells Are Decreased in Active Patients with Ulcerative Colitis but Not with Crohn's Disease
A1 Arribas Rodríguez, Elisa
A1 González de Castro, Carolina
A1 Fiz López, Aida
A1 Prado Moura, Ángel de
A1 Martín Muñoz, Álvaro
A1 Fernández Salazar, Luis Ignacio
A1 Barrio, Jesús
A1 Izquierdo, Sandra
A1 García Alonso, Francisco Javier
A1 Andrés Asenjo, Beatriz de
A1 García Abril, José María
A1 Romero de Diego, Alejandro Iván
A1 Sánchez González, Javier
A1 Santander, Cecilio
A1 Arranz Sanz, Eduardo
A1 Chaparro, María
A1 Garrote Adrados, José Antonio
A1 Gisbert, Javier P.
A1 Bernardo Ordiz, David
K1 Inmunología
K1 Gastroenterología
K1 Biología celular
K1 Patología humana
K1 Células dendríticas convencionales
K1 Humano
K1 Enfermedad inflamatoria intestinal
K1 2412 Inmunología
K1 3205 Medicina Interna
K1 2407 Biología Celular
AB This study aimed to characterize human intestinal conventional dendritic cells (cDCs) in health and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD). Three cDC subsets (CD103− cDC2, CD103+ cDC2, and cDC1) were identified from lamina propria mononuclear cells. Their phenotype and function were analyzed in healthy and IBD-inflamed gut tissues. In the healthy gut, cDC2 predominated over cDC1, with CD103+ cDC2 dominating the duodenum and CD103− cDC2 prevalent in the ileum and colon. CD103+ cDC2 expressed higher PD-L1 and produced more IL-10. In culture, CD103+ cDC2 increased proportionally unless inhibited by LPS. All subsets induced IL-10+ helper T-cell differentiation, with ileal cDCs being more stimulatory than colonic ones. In IBD, cDCs showed constitutively lower SIRPα expression across conditions. Notably, UC-inflamed colon exhibited reduced cDC1 and CD103+ cDC2, while CD-inflamed colon maintained these subsets but showed increased T-cell stimulation and IL-17+ T-cell priming. Intestinal cDC subsets prime IL-10+ helper T-cells in health. In UC, reduced cDC1 and CD103+ cDC2 in inflamed mucosa contrast with CD, suggesting distinct pathogenic mechanisms that could inform targeted therapies.
PB Wiley
SN 0014-2980
YR 2026
FD 2026
LK https://uvadoc.uva.es/handle/10324/83733
UL https://uvadoc.uva.es/handle/10324/83733
LA eng
NO European Journal of Immunology, vol. 56, n. 2, e70118.
NO Producción Científica
DS UVaDOC
RD 22-mar-2026